ATOS Atossa Therapeutics, Inc.
Listings ·
Atossa Therapeutics received a Nasdaq letter on February 17, 2026 saying it regained the $1.00 minimum closing bid price. The stock met the test on February 13, 2026, the last trading day before the extended deadline, after a February 2025 notice and an extension granted in August 2025.
The new deadline is February 17, 2026. Atossa said it may consider a reverse stock split if needed.
Nasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until August 20, 2025 to cure, and a second 180-day period is possible.
Jefferies will earn a commission of up to 3.0% on any shares sold. The stock last sold at $1.28 on November 15, 2024.
Atossa Therapeutics is a company whose lead program is (Z)-endoxifen, a proprietary active metabolite of tamoxifen. Its forward-looking statements describe clinical trials of (Z)-endoxifen in women with breast cancer and its ability to pursue a Duchenne muscular dystrophy (DMD) indication for the same molecule. The company says it is seeking an accelerated path to filing a New Drug Application with the U.S. Food and Drug Administration, which depends on the timing of FDA submissions and interactions. It also says it may be eligible for the Rare Pediatric Disease Priority Review Voucher program and for orphan-drug exclusivity for (Z)-endoxifen in DMD. The report lists the ability to continue as a going concern among its forward-looking statements, along with its ability to contract with third-party suppliers, manufacturers and clinical research organizations. The company also refers to efforts to deploy artificial intelligence in its own or its collaborators' product candidates, and it lists its common stock on the Nasdaq Capital Market.
| Product or program | What it is | Stage |
|---|---|---|
| (Z)-endoxifen | Proprietary active metabolite of tamoxifen; lead program, with breast cancer and DMD indications | Clinical trials in women with breast cancer planned or ongoing; DMD indication being pursued |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $21.2 million | $14.1 million |
| Net income (loss) | -$34.8 million | -$25.5 million |
| Cash from operations | -$29.8 million | -$21.0 million |
| Cash and equivalents | $41.3 million | $71.1 million |
Opinion Negative view
The filings say existing resources will likely not cover the next twelve months. The early drug data are small, and they do not solve the money problem.
Our latest story on this, dated Aug 21, 2025: "Atossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Nov 19, 2024: "Atossa Therapeutics sets up $100,000,000 at-the-market stock program with Jefferies". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 24, 2025: "Atossa Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 20, 2025". The story links the filing or release it is based on. Read the story.
Atossa Therapeutics, Inc. trades under the ticker ATOS on NASDAQ.
Atossa Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:ATOS; BMV:ATOS; GETTEX:YAG.
The SEC Central Index Key (CIK) for Atossa Therapeutics, Inc. is 1488039. Its filings are on SEC EDGAR.
9,979,298 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Atossa Therapeutics, Inc. under United States.
Our directory classifies Atossa Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Atossa Therapeutics, Inc. is US04962H7044.
aibio.space lists Atossa Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Atossa Therapeutics is a company whose lead program is (Z)-endoxifen, a proprietary active metabolite of tamoxifen. Its forward-looking statements describe clinical trials of (Z)-endoxifen in women with breast cancer and its ability to pursue a Duchenne muscular dystrophy (DMD) indication for the same molecule.
(Z)-endoxifen: Proprietary active metabolite of tamoxifen; lead program, with breast cancer and DMD indications Stage: Clinical trials in women with breast cancer planned or ongoing; DMD indication being pursued.
Atossa Therapeutics, Inc. reported a net loss of $34.8 million for the fiscal year ended Dec 31, 2025, and used $29.8 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio